Gain Therapeutics Q1 2025: Balance Sheet Insights
Ticker: GANX · Form: 10-Q · Filed: May 14, 2025 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, balance-sheet, quarterly-report, biotech
TL;DR
Gain Therapeutics Q1 2025 10-Q shows shifts in capital accounts. Check balance sheet for investor impact.
AI Summary
Gain Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company's financial statements show significant changes in its balance sheet accounts, including increases in Additional Paid-In Capital and Retained Earnings compared to the previous year. Specific figures for these accounts as of March 31, 2025, and December 31, 2024, are detailed within the filing.
Why It Matters
This filing provides a snapshot of Gain Therapeutics' financial health and capital structure as of Q1 2025, which is crucial for investors assessing the company's financial stability and growth potential.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, Gain Therapeutics faces inherent risks related to drug development and regulatory approvals, which are not fully detailed in this balance sheet-focused 10-Q.
Key Numbers
- $28.7M — Additional Paid-In Capital (As of March 31, 2025, indicating capital raised from stock issuance.)
- $27.1M — Additional Paid-In Capital (As of December 31, 2024, showing an increase in capital.)
- 2025-03-31 — Reporting Period End Date (The end date for the financial data presented in this 10-Q.)
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Filer of the 10-Q report
- March 31, 2025 (date) — End of the reporting period
- December 31, 2024 (date) — Previous fiscal year-end for comparison
- 28746041 (dollar_amount) — Additional Paid-In Capital as of March 31, 2025
- 27132588 (dollar_amount) — Additional Paid-In Capital as of December 31, 2024
FAQ
What was the net change in Retained Earnings between December 31, 2024, and March 31, 2025?
The filing indicates Retained Earnings were $0 as of March 31, 2025, and $0 as of December 31, 2024, suggesting no change or a net zero impact.
What is the value of Accumulated Other Comprehensive Income as of March 31, 2025?
The Accumulated Other Comprehensive Income as of March 31, 2025, is not explicitly stated with a dollar amount in the provided snippet, but it is listed as a balance sheet item.
What is the company's fiscal year end?
Gain Therapeutics, Inc.'s fiscal year ends on December 31.
What is the primary business of Gain Therapeutics, Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code for Gain Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What was the total number of public documents filed as part of this submission?
There were 93 public documents filed as part of this 10-Q submission.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Gain Therapeutics, Inc. (GANX).